The purpose of this study is to assess Motivational Interviewing (MI) to improve treatment engagement and outcome in subjects seeking treatment for substance abuse.

Condition	Treatment or Intervention	Phase
Substance-Related Disorders	Behavior: Behavior Therapy	Phase III

Further Study Details: 

Expected Total Enrollment:  422

Participants seeking treatment at the participating CTPs will be randomly assigned to either "standard" or "MET/MI" treatment, with a 1- and 3-month follow-up. Primary outcome measures will include (1) treatment retention (e.g., number of sessions/weeks completed, the rate of patients completing 3 or more subsequent sessions, and (2) substance use (e.g., urinalyses, days of opioid, cocaine, marijuana, alcohol use, rates of abstinence). Secondary outcomes will include motivation, psychosocial functioning, HIV risk behaviors, treatment utilization, and patient satisfaction. Process assessments will include measures of the working alliance as well as therapist adherence/competence ratings which will evaluate how effectively MET/MI was implemented. Participating CTPs will implement one of two independent protocols, depending on which is the best suited or feasible for the intake procedures at their clinic. Thus, following an invitation to participate, explanation of the study, and provision of informed consent, patients would complete a brief assessment battery followed by either:1) Random assignment to 3 individual sessions of standard treatment (treatment as usual) at the program versus 3 individual sessions of MET; or 2) Random assignment to 1 individual standard assessment/evaluation session.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

Individuals will be eligible for the protocol who: a)Are seeking outpatient treatment for any substance use disorder. b)Are 18 years of age or older. c)Are willing to participate in the protocol (e.g., to be randomized to treatment, be contacted for follow-up assessment, to have their sessions audiotaped). d)Are able to understand and provide written informed consent.

Exclusion Criteria:

Individuals will be excluded who: a)Are not sufficiently medically or psychiatrically stable to participate in outpatient treatment. b)Are seeking detoxification only, methadone maintenance, or residential inpatient treatment.

New York
      Lower Eastside Service Center (LESC), New York,  New York,  10007,  United States
Oregon
      Changepoint - Cedar Hills Blvd, Portland,  Oregon,  97292,  United States
      Changepoint, Inc., Portland,  Oregon,  97402,  United States
      ADAPT, Roseburg,  Oregon,  97470,  United States
      Willamette Family Treatment Services-Men's & Co-ed, Eugene,  Oregon,  97408,  United States
      Willamette Family Treatment Services, Eugene,  Oregon,  97402,  United States
Virginia
      Chesterfield County CSB- Substance Abuse Services, Chesterfield,  Virginia,  23832,  United States

Study chairs or principal investigators

Kathleen Carroll, Ph.D.,  Principal Investigator,  VA Connecticut Healthcare System   

Study ID Numbers:  NIDA-CTN-0005-1
Record last reviewed:  March 2004
Last Updated:  February 16, 2005
Record first received:  April 5, 2002
ClinicalTrials.gov Identifier:  NCT00032994
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08